Quantitative analysis for Zentalis Pharmaceuticals, Inc. (ZNTL) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Strong Buy (71.0) (grade A). Gem alpha score: 65.0. 30 signals analyzed (26 differentiated alt-data).
ZNTL stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-29 | $4.12 | $3.89 | $3.96 |
| 2026-05-11 | $4.47 | $4.03 | $4.14 |
| 2026-05-21 | $4.14 | $3.63 | $4.14 |
| 2026-06-03 | $3.94 | $3.62 | $3.72 |
| 2026-06-15 | $4.06 | $3.67 | $3.78 |
| 2026-06-26 | $4.07 | $3.68 | $4.04 |
| 2026-07-09 | $4.94 | $4.54 | $4.70 |
| 2026-07-21 | $5.37 | $5.00 | $5.01 |
| 2026-07-31 | $4.99 | $4.66 | $4.74 |
| 2026-08-12 | $4.31 | $4.08 | $4.29 |
| 2026-08-24 | $3.96 | $3.75 | $3.76 |
| 2026-09-03 | $4.12 | $3.73 | $4.11 |
How Zentalis Pharmaceuticals, Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| ZURA | Zura Bio Limited | $266M | 38.0 |
| IVA | Inventiva S.A. | $267M | — |
| PRE | Prenetics Global Limited | $261M | — |
| CCCC | C4 Therapeutics, Inc. | $272M | — |
View all Health Care stocks by valuation and signals →
Zentalis Pharmaceuticals, Inc. (ZNTL) scores Strong Buy (71.0), and the composite conceals a 53-point disagreement between its dimensions. It is strongest on competitive moat at 87 and technicals at 75, and weakest on AI Alpha (gem) at 34. A stock can carry competitive moat that high while AI Alpha (gem) sits at 34; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| competitive moat | 87 |
| technicals | 75 |
| valuation | 72 |
| earnings quality | 61 |
| analyst consensus | 42 |
| AI Alpha (gem) | 34 |
StoQuant analyzes 30 signals (26 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Zentalis Pharmaceuticals, Inc. (ZNTL): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/ZNTL"><img src="https://stoquant.com/badge/ZNTL.svg" alt="Zentalis Pharmaceuticals, Inc. (ZNTL) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.